CCR-CCL axes as key upstream influencers of pancreatic ductal adenocarcinoma: CCR2–CCL2, CCR5–CCL5, CCR4–CCL17/22, CCR6–CCL20, CCR7–CCL19/21
..."Among these immunosuppressive populations, Tregs are a key player in helping maintain an immunologically “cold” setting by suppressing effector immune responses via paracrine signaling and transcriptional modulation involving proteins like CTLA-4, PD-1, IL-10, TGF-β, and FOXP3, among others (83, 91, 169). In PDAC and colon cancer investigations, the CCR5–CCL5 signaling axis seems to have a large influence over these proteins"...
..."Leronlimab—an IgG4 monoclonal antibody for CCR5—also demonstrates translational potential in PDAC via activity in TNBC-centered trials (150). A pooled analysis of three mTNBC studies (NCT03838367, NCT04313075, NCT04504942) showed that higher doses (525-700mg), compared to lower doses (350-525mg), resulted in >75% improvement in mPFS and mOS, with outcomes reaching 6.1 months and over 12 months, respectively (222). CytoDyn, the developers of leronlimab, has also announced through a press release that the high-dose patient arm showed subsequent PD-L1 upregulation—suggesting a potential combination therapy with CPIs—and that long-term follow-up observed >36 months of OS in some cases"...
Frontiers | CCR-CCL axes as key upstream influencers of pancreatic ductal adenocarcinoma: CCR2–CCL2, CCR5–CCL5, CCR4–CCL17/22, CCR6–CCL20, CCR7–CCL19/21 https://share.google/Nxh0Kj4AdwGOrw6Bi
..."Among these immunosuppressive populations, Tregs are a key player in helping maintain an immunologically “cold” setting by suppressing effector immune responses via paracrine signaling and transcriptional modulation involving proteins like CTLA-4, PD-1, IL-10, TGF-β, and FOXP3, among others (83, 91, 169). In PDAC and colon cancer investigations, the CCR5–CCL5 signaling axis seems to have a large influence over these proteins"...
..."Leronlimab—an IgG4 monoclonal antibody for CCR5—also demonstrates translational potential in PDAC via activity in TNBC-centered trials (150). A pooled analysis of three mTNBC studies (NCT03838367, NCT04313075, NCT04504942) showed that higher doses (525-700mg), compared to lower doses (350-525mg), resulted in >75% improvement in mPFS and mOS, with outcomes reaching 6.1 months and over 12 months, respectively (222). CytoDyn, the developers of leronlimab, has also announced through a press release that the high-dose patient arm showed subsequent PD-L1 upregulation—suggesting a potential combination therapy with CPIs—and that long-term follow-up observed >36 months of OS in some cases"...
Frontiers | CCR-CCL axes as key upstream influencers of pancreatic ductal adenocarcinoma: CCR2–CCL2, CCR5–CCL5, CCR4–CCL17/22, CCR6–CCL20, CCR7–CCL19/21 https://share.google/Nxh0Kj4AdwGOrw6Bi
8
